Search bioRxiv⌕ Search

Biology subjects

Maj, P.

Publications and source records attributed to Maj, P..

2 recordsLinked to original sources

Modulating backbone flexibility in hydroxamate siderophores for improved iron chelation and peptide nucleic acid (PNA) delivery into bacteria

Peptide nucleic acid (PNA) is a synthetic oligonucleotide analog with a peptide-based backbone that selectively binds with high affinity to natural nucleic acids. PNA is a valuable tool in antisense technology with potential antibacterial applications. However, PNA cannot penetrate bacterial cells alone. To address this, we explored iron chelators - siderophores - as PNA carriers. Bacteria acquire iron through siderophores, which are transported via specific TonB-dependent receptors in the bacterial envelope. Previously, we demonstrated that a synthetic hydroxamate-type siderophore (SL) exploited this transport system to deliver PNA into bacterial cells, achieving a gene-silencing effect. However, this transport was limited to an Escherichia coli mutant with continuous iron uptake, and was not observed in wild-type E. coli. In this study, we developed a new synthetic siderophore (SGLY) with glycine spacers between modified ornithine residues for enhanced flexibility and iron-binding. We also synthesized marine siderophore analogs (MGLY and MALA) inspired by natural moanachelins. Using circular dichroism spectroscopy, spectrophotometric assays, and molecular dynamics simulations, we confirmed iron binding. Growth recovery experiments showed SGLY recognition and internalization via the TonB-dependent transport system, likely using hydroxamate siderophore pathways. The MGLY and MALA siderophores showed lower growth promotion than SGLY, indicating less efficient internalization. Molecular docking revealed high affinity of SGLY for E. coli receptors involved in the uptake of hydroxamate siderophores. However, upon conjugation to PNA, all three siderophores effectively delivered PNA into E. coli cells. We confirmed PNA-mediated gene silencing using fluorescence measurements and confocal microscopy.

biochemistry↗

Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19

Background: Recent reports on the use of hydroxychloroquine (HCQ) alone, or combined with azithromycin (AZM) in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have raised cardiac safety concerns. Currently, there is limited mechanistic data evaluating cardiac safety with HCQ and AZM therapy. Methods: Using comprehensive In Vitro ProArrhythmia Assay (CiPA) Schema IC50 paradigms, we examined the cardiac electrophysiological effects of HCQ and HCQ/AZM. Molecular modelling explored HCQ and AZM binding properties to hERG. Langendorff-perfused guinea-pig hearts were electrically and optically mapped by multi-electrode array and voltage (RH237) and Ca2+ (Rhod-2 AM) dyes. Human action potential and ion current reconstructions were performed in silico. Results: HCQ blocked IKr and IK1 with IC50 concentrations (10+-0.6 and 34+-5.0 microM) within the therapeutic range observed clinically. HCQ also blocked INa and ICaL but at higher IC50, whilst Ito and IKs were unaffected. Contrastingly, AZM produced minor inhibition of INa, ICaL, IKs, and IKr,, with no effect on IK1 and Ito. HCQ + AZM combined inhibited IKr and IK1 with IC50s of 7.7 +- 0.8 microM and 30.4 +- 3.0 microM, but spared INa, ICaL and Ito,. Molecular modelling confirmed potential HCQ binding to hERG. Cardiac mapping and ECG studies in isolated hearts demonstrated that HCQ slowed heart rate and ventricular conduction with associated prolongation of PR, QRS and QT intervals. Optical mapping demonstrated, and prolonged, more heterogeneous, action potential durations and intracellular Ca2+ transients. These effects were accentuated with combined HCQ+AZM treatment, which elicited electrical alternans, re-entrant circuits and wave breaks. Reconstruction in a human in-silico model demonstrated that this is attributable to the integrated action of HCQ and AZM reducing IKr, IKs and IK1. Conclusions: These data provide an electrophysiological basis for recent FDA guidelines cautioning against combined HCQ/AZM administration for the treatment of Covid-19 on the grounds of potential cardiac safety. We would strongly recommend monitoring of electrocardiographic QT interval with the use of this combination of medications.Competing Interest StatementThe authors have declared no competing interest.

pharmacology and toxicology↗